Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
Public ClinicalTrials.gov record NCT00680186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication
Study identification
- NCT ID
- NCT00680186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 2,589 participants
Conditions and interventions
Conditions
Interventions
- Warfarin Drug
- Dabigatran etexilate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Apr 30, 2011
- Completion
- Not listed
- Last update posted
- May 18, 2014
Started 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.46.01073 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 1160.46.01044 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1160.46.01068 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 1160.46.01071 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1160.46.01060 Boehringer Ingelheim Investigational Site | Stony Brook | New York | — | — |
| 1160.46.01061 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1160.46.01059 Boehringer Ingelheim Investigational Site | Bend | Oregon | — | — |
| 1160.46.01063 Boehringer Ingelheim Investigational Site | Corvallis | Oregon | — | — |
| 1160.46.01055 Boehringer Ingelheim Investigational Site | Summerville | South Carolina | — | — |
| 1160.46.01062 Boehringer Ingelheim Investigational Site | Bellevue | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 210 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00680186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00680186 live on ClinicalTrials.gov.